ICER finds AstraZeneca’s blood pressure pill Baxfendy not cost-effective at $10,950 a year

ICER released a report saying the clinical benefits of AstraZeneca’s new blood pressure medication Baxfendy do not justify its listed price.

The agency noted the drug is priced at $10,950 per patient per year, a level it considers excessive relative to the health gains observed.

The finding may influence insurers and health systems when deciding whether to cover the therapy, potentially limiting its market uptake.

No additional data on efficacy or safety beyond the cost assessment were provided in the report.